NEWS
Falling Walls 2024. Science Breakthroughs of the Year 2024 | Pitches
Falling Walls 2024. Science Breakthroughs of the Year 2024 | Pitches ActiTrexx has been [...]
SAT.1 Regionalmagazin features ActiTrexx GmbH as an example for a biotech start-up in Rhineland-Palatinate.
ActiTrexx GmbH was featured in SAT.1 Regionalmagazin as an example for a biotech start-up [...]
ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease
Mainz, Germany, 19 March 2024 – ActiTrexx GmbH, a clinical-stage company focusing on the activation [...]
Pioniergeist Preisverleihung 2022
ActiTrexx erhält den mit 15.000 Euro dotierten ersten Preis für die Entwicklung der „ATreg“ [...]
Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection
As the first company, alongside the Life Science Factory team, we moved to the [...]
PUBLICATIONS
- Using immuno-PET imaging to monitor kinetics of T cell-mediated inflammation and treatment efficiency in a humanized mouse model for GvHD. Eur J Nucl Med Mol Imaging. [Pektor S, Schlöder J, Klasen B, Bausbacher N, Wagner DC, Schreckenberger M, Grabbe S, Jonuleit H, Miederer M.]
- Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells. International Journal of Molecular Sciences. [Schlöder J, Berges C, Luessi F, Jonuleit H.]
- Novel Concept of CD4-Mediated Activation of Regulatory T Cells for the Treatment of Graft-Versus-Host Disease. Front Immunol. [Schlöder J, Berges C, Tuettenberg A, Jonuleit H.]
- Editorial: Current Concepts of Cellular and Biological Drugs to Modulate Regulatory T Cell Activity in the Clinic. Front Immunol. [Jonuleit H, Bopp T.]
- Kinome Profiling of Regulatory T Cells: A Closer Look into a Complex Intracellular Network. PLoS One. [Tuettenberg A, Hahn SA, Mazur J, Gerhold-Ay A, Scholma J, Marg I, Ulges A, Satoh K, Bopp T, Joore J, Jonuleit H.]
- Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells. Int J Mol Sci. [Trinschek B, Luessi F, Gross CC, Wiendl H, Jonuleit H.]
- Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis. PLoS ONE. [Trinschek B, Luessi F, Haas J, Wildemann B, Zipp F, et al.]
- In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med. [Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH.]
- Boosting regulatory T cell function by CD4 stimulation enters the clinic. Front Immunol. [Becker C, Bopp T, Jonuleit H.]
- CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J Allergy Clin Immunol. [Martin H, Reuter S, Dehzad N, Heinz A, Bellinghausen I, Saloga J, Haasler I, Korn S, Jonuleit H, Buhl R, Becker C, Taube C.]
- Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood. [Becker C, Taube C, Bopp T, Becker C, Michel K, Kubach J, Reuter S, Dehzad N, Neurath MF, Reifenberg K, Schneider FJ, Schmitt E, Jonuleit H.]